465 related articles for article (PubMed ID: 31336983)
21. Alpha-v integrins as therapeutic targets in oncology.
Nemeth JA; Nakada MT; Trikha M; Lang Z; Gordon MS; Jayson GC; Corringham R; Prabhakar U; Davis HM; Beckman RA
Cancer Invest; 2007 Oct; 25(7):632-46. PubMed ID: 18027153
[TBL] [Abstract][Full Text] [Related]
22. Integrin-mediated regulation of epidermal wound functions.
DiPersio CM; Zheng R; Kenney J; Van De Water L
Cell Tissue Res; 2016 Sep; 365(3):467-82. PubMed ID: 27351421
[TBL] [Abstract][Full Text] [Related]
23. The role of integrins in glioma biology and anti-glioma therapies.
Tabatabai G; Tonn JC; Stupp R; Weller M
Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
[TBL] [Abstract][Full Text] [Related]
24. Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells.
Baciu PC; Suleiman EA; Deryugina EI; Strongin AY
Exp Cell Res; 2003 Nov; 291(1):167-75. PubMed ID: 14597417
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of the coxsackie and adenovirus receptor downregulates αvβ3 and αvβ5 integrin expression and reduces cell adhesion and migration.
Majhen D; Stojanović N; Špeljko T; Brozovic A; De Zan T; Osmak M; Ambriović-Ristov A
Life Sci; 2011 Aug; 89(7-8):241-9. PubMed ID: 21712047
[TBL] [Abstract][Full Text] [Related]
26. (99m)Tc-HisoDGR as a Potential SPECT Probe for Orthotopic Glioma Detection via Targeting of Integrin α5β1.
Zhao H; Gao H; Zhai L; Liu X; Jia B; Shi J; Wang F
Bioconjug Chem; 2016 May; 27(5):1259-66. PubMed ID: 27098436
[TBL] [Abstract][Full Text] [Related]
27. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression.
Jiang Y; Dai J; Yao Z; Shelley G; Keller ET
Mol Cancer Res; 2017 Jul; 15(7):875-883. PubMed ID: 28314844
[TBL] [Abstract][Full Text] [Related]
28. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.
Yokosaki Y; Tanaka K; Higashikawa F; Yamashita K; Eboshida A
Matrix Biol; 2005 Sep; 24(6):418-27. PubMed ID: 16005200
[TBL] [Abstract][Full Text] [Related]
29. Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review.
Kobayashi M; Sawada K; Kimura T
Cancers (Basel); 2017 Jul; 9(7):. PubMed ID: 28698469
[TBL] [Abstract][Full Text] [Related]
30. Integrin control of tumor invasion.
Missan DS; DiPersio M
Crit Rev Eukaryot Gene Expr; 2012; 22(4):309-24. PubMed ID: 23272801
[TBL] [Abstract][Full Text] [Related]
31. RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field.
Ludwig BS; Kessler H; Kossatz S; Reuning U
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916607
[TBL] [Abstract][Full Text] [Related]
32. A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.
Hoffmann S; He S; Jin M; Ehren M; Wiedemann P; Ryan SJ; Hinton DR
BMC Ophthalmol; 2005 Jun; 5():16. PubMed ID: 15987521
[TBL] [Abstract][Full Text] [Related]
33. Cerebral ischemia-induced angiogenesis is dependent on tumor necrosis factor receptor 1-mediated upregulation of α5β1 and αVβ3 integrins.
Huang H; Huang Q; Wang F; Milner R; Li L
J Neuroinflammation; 2016 Sep; 13(1):227. PubMed ID: 27586239
[TBL] [Abstract][Full Text] [Related]
34. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.
Rüegg C; Alghisi GC
Recent Results Cancer Res; 2010; 180():83-101. PubMed ID: 20033379
[TBL] [Abstract][Full Text] [Related]
35. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ
J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338
[TBL] [Abstract][Full Text] [Related]
36. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
Mitjans F; Meyer T; Fittschen C; Goodman S; Jonczyk A; Marshall JF; Reyes G; Piulats J
Int J Cancer; 2000 Sep; 87(5):716-23. PubMed ID: 10925366
[TBL] [Abstract][Full Text] [Related]
37. Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology.
Vehlow A; Storch K; Matzke D; Cordes N
Recent Results Cancer Res; 2016; 198():89-106. PubMed ID: 27318682
[TBL] [Abstract][Full Text] [Related]
38. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells.
Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M
Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979
[TBL] [Abstract][Full Text] [Related]
39. Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin.
Pelillo C; Bergamo A; Mollica H; Bestagno M; Sava G
J Cell Biochem; 2015 Oct; 116(10):2385-96. PubMed ID: 25857463
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Extra-Cellular Matrix-Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors.
Lorusso G; Rüegg C; Kuonen F
Front Oncol; 2020; 10():1231. PubMed ID: 32793493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
